AR073603A1 - Combinaciones sinergicas de un inhibidor macrociclico del vhc y un nucleosido - Google Patents
Combinaciones sinergicas de un inhibidor macrociclico del vhc y un nucleosidoInfo
- Publication number
- AR073603A1 AR073603A1 ARP090103573A ARP090103573A AR073603A1 AR 073603 A1 AR073603 A1 AR 073603A1 AR P090103573 A ARP090103573 A AR P090103573A AR P090103573 A ARP090103573 A AR P090103573A AR 073603 A1 AR073603 A1 AR 073603A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compound
- pharmaceutically acceptable
- hcv
- combination
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 239000002777 nucleoside Substances 0.000 title 1
- 150000003833 nucleoside derivatives Chemical class 0.000 title 1
- 230000002195 synergetic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 10
- 150000003839 salts Chemical class 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 239000011885 synergistic combination Substances 0.000 abstract 2
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se relaciona con una combinacion sinérgica del compuesto de la formula (1), o una de sus sales farmacéuticamente aceptables, y el compuesto de la formula (2), o una de sus sales farmacéuticamente aceptables. Reivindicacion 1: Una combinacion sinérgica que comprende el compuesto de la formula (1) o una de sus sales farmacéuticamente aceptables, y el compuesto de la formula (2), o una de sus sales farmacéuticamente aceptables; o un éster profármaco de éste, que puede representarse mediante la formula (3), donde R1 es hidrogeno y R2 es CO-alquilo C1-18; o R2 es hidrogeno y R1 es CO-alquilo C1-18; o ambos R1 y R2 son CO-alquilo C1-18; o una de sus sales farmacéuticamente aceptables. Reivindicacion 2: La combinacion de la reivindicacion 1, donde el compuesto de la formula (1) se combina con un compuesto de la formula (2). Reivindicacion 3: La combinacion de la reivindicacion 1, donde el compuesto de la formula (1) se combina con un compuesto de la formula (3). Reivindicacion 8: La combinacion de cualquiera de las reivindicaciones 1 a 7, combinadas con un agente adicional seleccionado entre ribarivina e interferon. Reivindicacion 10: Un producto que comprende el compuesto de la formula (1) y el compuesto de la formula (2) o de la formula (3), todo segun lo definido en la reivindicacion 1, como una preparacion combinada para uso simultáneo, separado o secuencial en el tratamiento de VHC.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08164612 | 2008-09-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073603A1 true AR073603A1 (es) | 2010-11-17 |
Family
ID=40076811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103573A AR073603A1 (es) | 2008-09-18 | 2009-09-17 | Combinaciones sinergicas de un inhibidor macrociclico del vhc y un nucleosido |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20110171174A1 (es) |
| EP (1) | EP2341907A1 (es) |
| JP (1) | JP2012502956A (es) |
| KR (1) | KR20110054056A (es) |
| CN (1) | CN102164602A (es) |
| AP (1) | AP2011005608A0 (es) |
| AR (1) | AR073603A1 (es) |
| AU (1) | AU2009294622A1 (es) |
| BR (1) | BRPI0919404A2 (es) |
| CA (1) | CA2737835A1 (es) |
| CO (1) | CO6351740A2 (es) |
| EA (1) | EA201170456A1 (es) |
| EC (1) | ECSP11010902A (es) |
| IL (1) | IL211599A0 (es) |
| MX (1) | MX2011002896A (es) |
| PA (1) | PA8842901A1 (es) |
| TW (1) | TW201023858A (es) |
| UY (1) | UY32128A (es) |
| WO (1) | WO2010031829A1 (es) |
| ZA (1) | ZA201102047B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI454476B (zh) | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物 |
| CA2737376A1 (en) | 2008-09-17 | 2010-03-25 | Boehringer Ingelheim International Gmbh | Combination of hcv ns3 protease inhibitor with interferon and ribavirin |
| NZ598465A (en) | 2009-10-30 | 2013-10-25 | Boehringer Ingelheim Int | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin |
| WO2011128378A1 (en) * | 2010-04-13 | 2011-10-20 | Janssen Pharmaceuticals, Inc. | Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside |
| WO2011153712A1 (en) * | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
| US8877731B2 (en) | 2010-09-22 | 2014-11-04 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
| CN103228278A (zh) * | 2010-09-30 | 2013-07-31 | 贝林格尔.英格海姆国际有限公司 | 治疗hcv感染的组合疗法 |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8466159B2 (en) * | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) * | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| SI2909205T1 (sl) | 2012-10-19 | 2017-02-28 | Bristol-Myers Squibb Company | 9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| GEP201706757B (en) | 2012-12-21 | 2017-10-25 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| US9580463B2 (en) | 2013-03-07 | 2017-02-28 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2018017989A1 (en) * | 2016-07-22 | 2018-01-25 | Janssen Pharmaceuticals, Inc. | Combination therapy regimen for treatment of selected hcv genotypes |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20070211A1 (es) * | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| CL2007000361A1 (es) * | 2006-02-09 | 2008-01-25 | Wyeth Corp | Combinacion que comprende un inhibidor de la arn polimerasa del virus de la hepatitis c (vhc) y un inhibidor de la proteasa del vhc; composicion farmaceutica que la comprende; y uso de la combinacion para tratar trastornos asociados con vhc. |
| WO2007092616A2 (en) * | 2006-02-09 | 2007-08-16 | Schering Corporation | Combinations comprising hcv protease inhibitor(s) and hcv polymerase inhibitor(s), and methods of treatment related thereto |
| CN101979397B (zh) * | 2006-10-10 | 2013-11-06 | 美迪维尔公司 | Hcv核苷类抑制剂 |
-
2009
- 2009-09-17 AR ARP090103573A patent/AR073603A1/es not_active Application Discontinuation
- 2009-09-17 TW TW098131308A patent/TW201023858A/zh unknown
- 2009-09-18 AU AU2009294622A patent/AU2009294622A1/en not_active Abandoned
- 2009-09-18 AP AP2011005608A patent/AP2011005608A0/xx unknown
- 2009-09-18 JP JP2011527331A patent/JP2012502956A/ja active Pending
- 2009-09-18 PA PA20098842901A patent/PA8842901A1/es unknown
- 2009-09-18 BR BRPI0919404A patent/BRPI0919404A2/pt not_active Application Discontinuation
- 2009-09-18 WO PCT/EP2009/062096 patent/WO2010031829A1/en not_active Ceased
- 2009-09-18 US US13/119,466 patent/US20110171174A1/en not_active Abandoned
- 2009-09-18 UY UY0001032128A patent/UY32128A/es unknown
- 2009-09-18 CA CA2737835A patent/CA2737835A1/en not_active Abandoned
- 2009-09-18 CN CN2009801373764A patent/CN102164602A/zh active Pending
- 2009-09-18 MX MX2011002896A patent/MX2011002896A/es not_active Application Discontinuation
- 2009-09-18 EA EA201170456A patent/EA201170456A1/ru unknown
- 2009-09-18 KR KR1020117008646A patent/KR20110054056A/ko not_active Withdrawn
- 2009-09-18 EP EP09783155A patent/EP2341907A1/en not_active Withdrawn
-
2011
- 2011-03-07 IL IL211599A patent/IL211599A0/en unknown
- 2011-03-15 CO CO11032140A patent/CO6351740A2/es not_active Application Discontinuation
- 2011-03-17 EC EC2011010902A patent/ECSP11010902A/es unknown
- 2011-03-17 ZA ZA2011/02047A patent/ZA201102047B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO6351740A2 (es) | 2011-12-20 |
| TW201023858A (en) | 2010-07-01 |
| EA201170456A1 (ru) | 2011-08-30 |
| UY32128A (es) | 2010-03-26 |
| ECSP11010902A (es) | 2011-06-30 |
| JP2012502956A (ja) | 2012-02-02 |
| AU2009294622A1 (en) | 2010-03-25 |
| IL211599A0 (en) | 2011-05-31 |
| WO2010031829A1 (en) | 2010-03-25 |
| KR20110054056A (ko) | 2011-05-24 |
| US20110171174A1 (en) | 2011-07-14 |
| CN102164602A (zh) | 2011-08-24 |
| BRPI0919404A2 (pt) | 2015-12-15 |
| AP2011005608A0 (en) | 2011-04-30 |
| PA8842901A1 (es) | 2010-04-21 |
| EP2341907A1 (en) | 2011-07-13 |
| ZA201102047B (en) | 2012-08-29 |
| CA2737835A1 (en) | 2010-03-25 |
| MX2011002896A (es) | 2011-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073603A1 (es) | Combinaciones sinergicas de un inhibidor macrociclico del vhc y un nucleosido | |
| AR072261A1 (es) | Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos. | |
| ECSP15015737A (es) | Análogos de 2'-cloro nucleósido para infección por vhc | |
| ECSP10010556A (es) | Piridinas y pirazinas como inhibidores de pi3k | |
| CL2009000429A1 (es) | Compuestos derivados de carbamoil-heterociclos fusionados, en especial pirrolo[3,2-c]piridin-2-carboxamidas, inhibidores de smo; composicion farmaceutica que comprende dichos compuestos; y uso en la profilaxis o tratamiento del cancer. | |
| NI201300107A (es) | Derivados de nucleósidos 2' - sustituidos y métodos de uso de los mismos para el tratamiento de enfermedades virales. | |
| CO6620055A2 (es) | Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos | |
| CO6361922A2 (es) | Inhibidores del virus de la hepatitis c | |
| NI201400023A (es) | Derivados de pirrolopirimidina y purina | |
| CU20140068A7 (es) | Triazolopiridinas sustituidas | |
| CR20160140A (es) | Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih | |
| UY31679A1 (es) | Inhibidores de cinasa pim y metodos para su uso | |
| DOP2016000250A (es) | Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa | |
| SG148178A1 (en) | Indozolone derivatives as 11b-hsd1 inhibitors | |
| CR9587A (es) | Derivados de piridazina | |
| ECSP077648A (es) | Tetrazolilos macrociclicos como inhibidores de serina proteasa de hepatitis c | |
| SV2011003853A (es) | Compuestos organicos | |
| ECSP12011935A (es) | Triazolopiridinas | |
| AR077765A1 (es) | Inhibidores de los virus flaviviridae | |
| AR061238A1 (es) | Compuestos de oxilmilo macrociclico inhibidores de proteasa de hepatitis c | |
| ECSP077649A (es) | Piridazinonilos macrociclicos como inhibidores de serina proteasa de hepatitis c | |
| CU20120171A7 (es) | Triazolopiridinas sustituidas | |
| ECSP13013011A (es) | Triazolopiridinas | |
| UY30476A1 (es) | Noveles compuestos derivados n-sustituidos de la 3-oxoisoindolin-1-carboxamida, sus sales aceptables, composiciones farmaccuticas y aplicaciones. | |
| PE20151892A1 (es) | Compuestos tetraciclicos sustituidos con heterociclo y metodos de uso de los mismos para el tratamiento de enfermedades viricas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |